CXCL5 expression is associated with active signals of macrophages in the microenvironment of papillary thyroid carcinoma
- Tho Ngoc-Quynh Le 1, Minh-Khang Le 2, Minh-Xuan Dang 1, Tetsuo Kondo 2
- 1Department of Pathology, University Medical Center, Ho Chi Minh City 70000, Viet Nam.
- 2Department of Pathology, University of Yamanashi, Chuo 409-3821, Japan.
- 0Department of Pathology, University Medical Center, Ho Chi Minh City 70000, Viet Nam.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High C-X-C motif chemokine ligand 5 (CXCL5) expression indicates advanced papillary thyroid carcinoma (PTC) and poor prognosis. CXCL5 may be a therapeutic target for advanced PTC, impacting tumor immunology and microenvironment.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- C-X-C motif chemokine ligand 5 (CXCL5) is a granulocyte-attracting chemokine implicated in papillary thyroid carcinoma (PTC) progression.
- The in vivo effects of CXCL5 on PTC tumor cells and their microenvironment remain largely unelucidated.
Purpose Of The Study
- To investigate the biological effects of CXCL5 on PTC tumor cells.
- To analyze the impact of CXCL5 on the tumor microenvironment.
- To determine the association of CXCL5 with clinical progression in PTC.
Main Methods
- Utilized The Human Cancer Genome Atlas (TCGA) - thyroid carcinoma (THCA) dataset comprising 500 PTC patients.
- Performed differential gene expression analysis (DEA) and pathway analysis on CXCL5 expression.
- Correlated CXCL5 expression with immune profiles, microenvironment components, and clinical outcomes.
Main Results
- CXCL5 expression was significantly associated with specific genes (PBPP, SLC11A1, MRC1) and immune profiles.
- Higher CXCL5 expression correlated with increased activity in RAS-RAF, NF-kB, PRC2, IL2, IL5, and Wnt pathways.
- CXCL5 strongly correlated with macrophage activity and served as an indicator for advanced tumor stage, nodal metastasis, and poorer prognosis in PTC.
Conclusions
- CXCL5 is a significant biomarker for PTC, closely linked to tumor immunology and microenvironment.
- Elevated CXCL5 expression signifies more advanced disease and worse prognosis in PTC patients.
- Targeting CXCL5 presents a potential therapeutic strategy for advanced PTC.
Related Experiment Videos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.

